Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Zineh

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology and Therapeutics|April 11, 2013
Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluationI Zineh, J Woodcock
Clinical Pharmacology and Therapeutics|February 20, 2014
Next-generation medicines: past regulatory experience and considerations for the futureM A Pacanowski, C Leptak, I Zineh
Clinical Pharmacology and Therapeutics|April 22, 2014
Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policyV Sinha, P Zhao, S M Huang, et al.
Clinical Pharmacology and Therapeutics|May 22, 2013
Office of clinical pharmacology science day: a forum to stimulate innovation in clinical pharmacologyR P Owen, L Jain, L Zhang, et al.
Clinical Pharmacology and Therapeutics|April 15, 2015
Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and UtilizationS Amur, L LaVange, I Zineh, et al.
Clinical Pharmacology and Therapeutics|January 17, 2017
Toward greater insights on pharmacokinetics and exposure-response relationships for therapeutic biologics in oncology drug developmentY Wang, B Booth, A Rahman, et al.
The Pharmacogenomics Journal|January 13, 2006
Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogeneticsA L Beitelshees, I Zineh, H N Yarandi, et al.
The AAPS Journal|December 21, 2019
Current Perspectives on Ligand-Binding Assay Practices in the Quantification of Circulating Therapeutic Proteins for Biosimilar Biological Product DevelopmentT M Thway, Y M Wang, B P Booth, et al.
Clinical Pharmacology and Therapeutics|October 12, 2016
Improving the tools of clinical pharmacology: Goals for 2017 and beyondI Zineh, D Abernethy, Ceca Hop, et al.
Clinical Pharmacology and Therapeutics|February 22, 2014
PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathwaysM D L T Vieira, M-J Kim, S Apparaju, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology and Therapeutics|April 11, 2013
Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluationI Zineh, J Woodcock
Clinical Pharmacology and Therapeutics|February 20, 2014
Next-generation medicines: past regulatory experience and considerations for the futureM A Pacanowski, C Leptak, I Zineh
Clinical Pharmacology and Therapeutics|April 22, 2014
Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policyV Sinha, P Zhao, S M Huang, et al.
Clinical Pharmacology and Therapeutics|May 22, 2013
Office of clinical pharmacology science day: a forum to stimulate innovation in clinical pharmacologyR P Owen, L Jain, L Zhang, et al.
Clinical Pharmacology and Therapeutics|April 15, 2015
Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and UtilizationS Amur, L LaVange, I Zineh, et al.
Clinical Pharmacology and Therapeutics|January 17, 2017
Toward greater insights on pharmacokinetics and exposure-response relationships for therapeutic biologics in oncology drug developmentY Wang, B Booth, A Rahman, et al.
The Pharmacogenomics Journal|January 13, 2006
Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogeneticsA L Beitelshees, I Zineh, H N Yarandi, et al.
The AAPS Journal|December 21, 2019
Current Perspectives on Ligand-Binding Assay Practices in the Quantification of Circulating Therapeutic Proteins for Biosimilar Biological Product DevelopmentT M Thway, Y M Wang, B P Booth, et al.
Clinical Pharmacology and Therapeutics|October 12, 2016
Improving the tools of clinical pharmacology: Goals for 2017 and beyondI Zineh, D Abernethy, Ceca Hop, et al.
Clinical Pharmacology and Therapeutics|February 22, 2014
PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathwaysM D L T Vieira, M-J Kim, S Apparaju, et al.
Pageof 2